Compare Genuine Parts Company (GPC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Mesoblast Limited — how do they compare? Genuine Parts Company trades at $135.22 (market cap $18.55B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Genuine Parts Company is far larger — about 8.6× Mesoblast Limited's market cap, and Genuine Parts Company pays a 3.16% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GPC | MESO | |
|---|---|---|
Market Cap | $18.55B | $2.16B |
Sector | Consumer Cyclical | Technology |
52-Week High | $149.26 | $20.96 |
52-Week Low | $92.47 | $12.88 |
Enterprise Value | $24.64B | $2.17B |
Dividend Yield | 3.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $135.63, up 2.14% today, with a bullish technical signal from moving averages but a bearish oscillator reading. The stock is supported by strong Q2 2026 earnings beats, with sales growth of 6% year-over-year and an adjusted EPS of $2.15 beating estimates. However, net income margin remains thin at 0.13% for 2025, and the P/E ratio is elevated at 542.52, indicating high valuation relative to earnings. Recent news highlights institutional buying interest and reaffirmed 2026 adjusted EPS guidance of $7.50 to $8.00.
The outlook for GPC is cautiously optimistic, with analyst consensus pointing to a $148.67 price target and a 'Buy' rating from 43% of covering analysts. Key opportunities include sustained industrial segment strength and dividend consistency, while risks involve margin pressure from inflation, high debt levels, and competitive pressures in the auto parts industry. Earnings growth and cost management are critical for future stock performance.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
